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Abstract
Nanotechnology is a thriving industry and has the potential to benefit society in
numerous ways. However, not all environmental and human health concerns of
nanomaterials have been addressed. Thus, the purpose of this research was to investigate
the toxicity and inflammation potential (using cytokines TNF-α and IL-6 as indicators) of
various sized copper nanoparticles (40, 60, and 80 nm) in rat alveolar macrophages.
Toxicity measurements were accomplished by means of in vitro techniques and toxicity
mechanisms were studied by measuring reactive oxygen species (ROS) production. In
addition, cytokine measurements used enzyme-linked immunosorbent assay (ELISA)
methods. Results show copper nanoparticles as gravely toxic to rat alveolar
macrophages; concentrations of only 10 µg/mL produced cell viability of less than 20
percent and membrane leakage increases of approximately 75 percent. However, the
copper nanoparticles did not produce a significant degree of ROS (only 2.5 fold
increases). Also, the toxicity showed a dose-dependent relationship, but not a significant
size dependency between the various sized copper nanoparticles.

Finally, minimal

induction of cytokines occurred; however, stimulation of rat alveolar macrophages by
lipopolysaccharide (LPS) and subsequent exposure to copper nanoparticles produced
elevated levels of both cytokines.

iv

Acknowledgments

I would like to express my appreciation to Dr. Charles Bleckmann, for his guidance and
support throughout the course of this thesis effort. I would also like to thank Dr. Saber
Hussain for his technical expertise in the field of in vitro toxicity methods. Also, thank
you to all of the Air Force Research Laboratory personnel who assisted me in my
research endeavor. Thank you to Dr. Laura Stolle, Ms. Kathy Szczublewski, and Mr.
Craig Murdock for all of the technical help with my laboratory adventures. Finally, thank
you to my wife and son for the patience and understanding throughout this entire process.

Brian M. Clarke

v

Table of Contents
Page
Abstract .............................................................................................................................. iv
Acknowledgments................................................................................................................v
Table of Contents ............................................................................................................... vi
List of Figures ......................................................................................................................x
List of Tables .................................................................................................................... xii
I. Introduction .....................................................................................................................1
Background...................................................................................................................1
Environmental Implications .........................................................................................3
Problem Identification ..................................................................................................4
Research Focus .............................................................................................................7
Research Questions ......................................................................................................7
Assumption and Limitations.........................................................................................8
Methodology Overview ................................................................................................8
II. Literature Review ..........................................................................................................10
Nanotoxicity ...............................................................................................................10
In Vivo Studies. ...........................................................................................................12
In Vitro Studies. ..........................................................................................................13
Reactive Oxygen Species. ...........................................................................................15
Copper ........................................................................................................................17
Copper Nanoparticles .................................................................................................21
Respiratory System.....................................................................................................24
Macrophages. .............................................................................................................24
vi

Page
Cytokines ....................................................................................................................28
Tumor Necrosis Factor-α. ..........................................................................................29
Interleukin-6. ..............................................................................................................30
TNF-α and IL-6 Studies. .............................................................................................30
Cellular Assays ...........................................................................................................31
MTS Assay. .................................................................................................................31
LDH Assay. .................................................................................................................32
ROS Assay. .................................................................................................................33
Cytokine Assay............................................................................................................33
III. Methodology ...............................................................................................................34
Overview ....................................................................................................................34
Cell Culture ................................................................................................................34
Nanoparticle Solutions ...............................................................................................35
Experiment Overview.................................................................................................36
Cell Counting..............................................................................................................36
Cell Plating.................................................................................................................36
Nanoparticle Dosing. .................................................................................................37
Cellular Assays ...........................................................................................................37
MTS Assay. .................................................................................................................37
LDH Assay. .................................................................................................................38
Time Study. .................................................................................................................39

vii

Page
ROS Assay. .................................................................................................................40
TNF-α Assay. ..............................................................................................................42
IL-6 Assay. ..................................................................................................................44
Dynamic Light Scattering...........................................................................................46
Statistical Analysis .....................................................................................................47
IV. Results and Analysis ...................................................................................................48
MTS Assay .................................................................................................................48
Time Study .................................................................................................................49
LDH Assay .................................................................................................................51
Reactive Oxygen Species ...........................................................................................52
Cytokine Analysis ......................................................................................................56
TNF-α Analysis. ..........................................................................................................57
IL-6 Analysis...............................................................................................................60
Dynamic Light Scattering...........................................................................................63
V. Discussion ....................................................................................................................64
Research Questions and Conclusions .........................................................................64
Suggestions for Further Research...............................................................................65
Appendix A. MTS Assay Protocol ....................................................................................67
Appendix B. LDH Assay Protocol.....................................................................................68
Appendix C. Reactive Oxygen Species Protocol ...............................................................69
Appendix D. TNF-α ELISA Protocol ................................................................................70
Appendix E. IL-6 ELISA Protocol ....................................................................................73
Bibliography ......................................................................................................................76
viii

Page
Vita ....................................................................................................................................86

ix

List of Figures
Page
Figure 1: Nanotechnology Research Funding (Tsuji, et al., 2006:43)................................ 5
Figure 2: Haber-Weiss Reaction (Brember, 1998:1071S) ................................................ 20
Figure 3. Chemical structure of MTS and the converted product of Formazan, which is a
measure of cell viability (CellTiter 96 AQueous One Solution Cell Proliferation Assay
Technical Bulletin) ..................................................................................................... 32
Figure 4. LDH Chemical Reaction (CytoTox-ONETM Homogenous Membrane Integrity
Assay Technical Bulletin) .......................................................................................... 32
Figure 5. MTS/LDH assay procedures ............................................................................. 38
Figure 6. Time study procedures ...................................................................................... 40
Figure 7. ROS procedures ................................................................................................. 41
Figure 8. Combined MTS results (Cu-40, 60 and 80 nanoparticles) ................................ 49
Figure 9. Cu-80 nanoparticle time study (≤ 8 hours) ........................................................ 50
Figure 10. Combined LDH results (Cu-40, 60 and 80 nanoparticles) .............................. 52
Figure 11. ROS production at 6 and 24 hours after exposure to Cu-40 nanoparticles ..... 54
Figure 12. ROS production at 6 and 24 hours after exposure to Cu-60 nanoparticles ..... 54
Figure 13. ROS production at 6 and 24 hours after exposure to Cu-80 nanoparticles ..... 55
Figure 14. ROS production at 6 and 24 hours after exposure to Positive Control
(hydrogen peroxide) ................................................................................................... 55
Figure 15. TNF-α produced after exposure to Cu-80 nanoparticles ................................. 58
Figure 16. Combined (Cu-40, 60, 80 and LPS) results of TNF-α produced .................... 60
x

Page
Figure 17. Combined (Cu-40, 60, 80 and LPS) results of IL-6 produced ........................ 62

xi

List of Tables
Page
Table 1. DoD Investment in nanotechnology over the past three years (in millions of
dollars) (Defense Nanotechnology Research and Development Programs, 2007) ...... 6
Table 2. DLS results, 0-and 24-hour time points .............................................................. 63

xii

IN VITRO TOXICITY AND INFLAMMATORY RESPONSE INDUCED BY COPPER
NANOPARTICLES IN RAT ALVEOLAR MACROPHAGES

I. Introduction

Background
Engineered nanomaterials have many potential benefits for society today and
nanotechnology use has increased significantly in recent years. In 2000, President Bill
Clinton deemed nanotechnology a top national priority and developed the National
Nanotechnology Initiative (National Nanotechnology Initiative). Nanotechnologies, and
specifically nanomaterials, are defined by the National Nanotechnology Initiative (NNI)
as: on a length scale of 1-100 nanometers, able to control on the atomic scale, and, able to
create novel devices with unique properties because of its function and size (Thomas and
Sayre, 2005:316). Human exposure to nano-sized materials is not entirely
unprecedented; natural particles produced by forest fires and volcanoes, and some viral
particles, are in the nano-size range (Oberdörster, E., 2004:1058). However, engineered
nanomaterials are manufactured in the laboratory; thus naturally occurring and
anthropogenic (i.e., automobile and industrial combustion products) ultrafine and nanosized particles are excluded (Thomas and Sayre, 2005:316).
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Different nanomaterials include nanoparticles, nanotubes, nanowires, and
fullerene derivatives (Holsapple, et al., 2005:12). Nanomaterials are being utilized in
more products as advancements continue in nanotechnology. For example, nanomaterials
are currently utilized in electronics, fuel cells, and personal-care products to include
sunscreen (Oberdörster, G., et al., 2005:825). Nanomaterials have also being used in
toothpastes, sanitary ware coatings, and even food products (Hoet, et al., 2004).
The small size and highly reactive properties of nanomaterials make them ideal to
serve as reaction catalysts (Thomas and Sayre, 2005:318). Nanomaterials possess
increased surface areas due to small diameters, and the ability to be more reactive than
larger counterparts. Increased surface area and particle quantities can lead to many
positive effects. Promising benefits from nanoparticle use include disease treatment in
various medicines and sensory use in intracellular mechanisms. Nanoparticles, due to
small size, are able to penetrate deeper into various tissues and display greater
intracellular uptake (Panyam and Labhasetwar, 2003:330). Uses include nanomaterials
as a drug delivery agent or as a biomarker in disease diagnosis (Oberdörster, G., et al.,
2005:824). Nanoparticles are close in size to many biomolecules; thus nanoparticles
serve as markers to track enzymes and receptor ligands (Thomas and Sayre, 2005:319).
Non-viral nanoparticulate systems have been tested as a delivery mechanism for
therapeutic agents targeting macrophages because of the vital role macrophages play in
the immune system, specifically the inflammatory response (Chellat, et al., 2005:7260).
Other studies have shown the ability for certain nanoparticles to successfully cross the
blood-brain barrier. Kreuter describes how an intravenously administered nano-sized
2

particle was able to cross the blood-brain barrier to treat intracranially transplanted
glioblastomas 101/8 in rats (2001:65).
Environmental Implications
Nanomaterials enter the environment through several routes and can subsequently
be transported via different environmental mediums to include air, soil, and water
(Oberdörster, G., et al., 2005:825). The large surface area and reactive properties of
nanoparticles may allow increased persistence in the environment, which can be a useful
property in remediation efforts (Holsapple, et al., 2005:12). Nanomaterials have been
tested for use as potential remediation agents to treat environmental contaminants. For
example, iron nanoparticles (Fe0) have been successfully utilized for the remediation of a
trichloroethene (TCE) contaminated water source (Liu, Y., et al., 2005:1344). Previous
remediation efforts have used iron fillings; however, iron nanoparticles’ increased
surface-to-volume ratio allows increased reactivity and has been more effective in
remediation efforts (Liu, Y., et al., 2005:1338). However, the effective transport of
nanoparticles in the environment has been limited by particle size in the subsurface.
Thus, special delivery methods may be needed for efficient nanoparticle transport to aid
in remediation efforts (Schrick, et al., 2004:2193).
Another subsequent use for nanomaterials is an antibacterial agent for such items
to include certain medical devices (Morrison, et al., 2006:138). Fullerene water
suspensions (FWS) have previously been tested for their antimicrobial properties against
Escherichia coli. Fullerene powder (C60) has an extremely low solubility in water;
however, one study’s aim was to mimic a potential environmental spill of C60 powder or
3

C60 and solvent mixture. The study showed that a FWS could be prepared for the
antimicrobial evaluation of nC60, which is equivalent to C60 when in contact with water or
other liquids (Lyon, et al., 2006:4360). Lyon and others showed antibacterial properties
of the FWS against the test organism Bacillis subtillis (2006:4362). E. Oberdörster also
showed bactericidal activity of C60 in an aquatic environment (2004:1061).
Problem Identification
Despite the potential benefits of nanotechnology, the knowledge base of human
health and environmental effects in the production and use of nanomaterials is
insufficient. Exposure to nanoparticles can occur through consumer product use and
disposal and potential spillage during shipping and handling (Chen, Z., et al., 2006:109).
In general, nanoparticle toxicity is related to the small particle size, the ease with which
the particles move and enter into cells, and the increased surface area of nanoparticles
(Dowling, 2004:33). As past experience has shown with other novel products,
acceptance of nanotechnology use will largely be based on if the public accepts the
potential risks in exchange for the established or promising benefits (Tsuji, et al.,
2006:42). Even though different nanoparticles display similar properties, not all
nanoparticles can be treated as equal and must be studied individually (Holsapple, et al.,
2005:12). In addition, many nanomaterials present unique properties because of the type
of surface coating applied on the material (Thomas and Sayre, 2005:318).
The United States Environmental Protection Agency (EPA) is concerned about
the unmanaged use of nanomaterials for various applications and the unknown
environmental transport processes that the materials may exhibit. The EPA states,
4

“Potentially harmful effects of nanotechnology may exist. These effects might relate to
the nature of nanoparticles themselves, the characteristics of the products made from
them, or the aspects of the manufacturing process involved” (US EPA Nanotechnology).
In addition, there is little research as to the potential ecotoxic effects of nanoparticles to
aquatic organisms. However, one difference exists because prokaryotes do not possess
the proper mechanisms for bulk transport of nano-sized particles as compared to
eukaryotes (Moore, et al., 2006:970). Nanomaterials are under constant investigation by
various industries. In recent years, the United States government has attempted to
coordinate research and regulatory needs in regards to the environmental, human health,
and safety risks of nanotechnology. However, most research involving nanotechnology
has focused on application and use. Environmental and human health effects have not
been a focus, as evidenced by the research funding shown in Figure 1 below. Overall,
human and environmental health research accounts for only four percent of the total
nanotechnology research funding budget in the United States (Tsuji, et al., 2006:42).

Figure 1: Nanotechnology Research Funding (Tsuji, et al., 2006:43)
5

In addition, the Department of Defense (DoD) has also focused on the benefits of
nanotechnology (see Table 1, below). For example, the DoD (through Defense Research
and Engineering) produces an annual report, the Defense Nanotechnology Research and
Development Programs, to discuss DoD nanotechnology programs, current and future
research, and recommendations for future activities involving nanotechnology.
Table 1. DoD Investment in nanotechnology over the past three years (in millions of
dollars) (Defense Nanotechnology Research and Development Programs, 2007)
FY2006 (Actual)
FY2007 (Estimate)
FY2008 (Request)
64.012
66.984
34.136
Army
45.460
45.188
27.140
Navy
89.907
70.855
63.817
Air Force
195.377
219.320
212.458
DARPA
5.800
5.000
7.200
DDR&E
19.882
9.650
39.801
CBDP
3.520
0.270
0.130
MDA
TOTAL
423.958
417.267
374.682
However, the DoD has also become increasingly concerned with the potential adverse
effects of nanoparticles. In July 2004, the United States Air Force funded a five-year, 5.5
million dollar project to develop a model that will ultimately predict biocompatible and
toxic effects of nanoparticles (DoD Funds). The Air Force hopes the project will
effectively evaluate the physiochemical characteristics of nanomaterials that cause
adverse effects, cellular uptake and translocation mechanisms by conducting in vitro
testing of several nanomaterials that range in sizes from 3 to 100 nm.
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Research Focus
Various in vitro and in vivo studies involving nanoparticles have been conducted;
yet little research has been done concerning copper nanoparticle toxicity. One in vivo
study examined copper nanoparticle toxicity via an ingestion exposure route (Chen, Z., et
al., 2006). My research focus will be on the use of alveolar macrophages due to the
crucial role that alveolar macrophages play within the immune system. Thus, an in vitro
study of alveolar macrophages is a good model to represent the respiratory system.
Different toxicity mechanisms can be measured by in vitro studies, and the sensitivity of
various nanoparticles can be measured using various cell lines. In vitro testing methods
provide a rapid and inexpensive method of screening the numerous synthetic chemicals
produced every year (Trohalaki, et al., 2002:499). However, in vitro cytotoxicity tests
can be used as a screening method, but not as a replacement for in vivo procedures and
evaluations.
Research Questions
1.) Are copper nanoparticles (40, 60, and 80 nm) toxic to alveolar macrophages?
2.) Is the toxicity size-dependent (i.e., difference in toxicity between the three sizes
of copper nanoparticles)?
3.) Do copper nanoparticles induce reactive oxygen species (ROS)?
4.) Do copper nanoparticles induce an inflammatory response (using cytokines TNFα and IL-6 as indicators)?

7

Assumption and Limitations
This research will focus on one cell line (rat alveolar macrophages); thus, not all
organ systems can be modeled. In addition, copper nanoparticle transport (i.e.,
toxicokinetics) throughout the body cannot be described by using an in vitro model. For
example, if an exposure occurred to a large amount of nanoparticles, the alveolar
macrophage clearance mechanisms may become overloaded. The particles, due to the
small size, may then be able to cross into epithelial tissue and the interstitial layer. An in
vitro model will not describe the transport to various organs within the body.
In vitro toxicity testing of nanoparticles present some novel challenges to toxicity
testing. Teeguarden and others explain that a nanoparticle dose is not static, but dynamic
and can be extremely complicated (2007:300). In addition, other factors, such as particle
size, particle number, and diffusion rates of the particle, must be considered during the
dosing process (2007:301). One potential problem is the dynamic nature and ability of
nanoparticles to “settle, diffuse, and aggregate differentially according to their size,
density, and surface physicochemistry,” as compared to soluble chemicals (Teeguarden,
et al., 2007:300-301). In addition, one must account for the dosing solutions used and its
applicable properties to include viscosity, density, and protein presence (Teeguarden, et
al., 2007:301).
Methodology Overview
The methodology used rat alveolar macrophages as the cell line for all in vitro
toxicity and cytokine experiments. The progression of assays started with basic toxicity
experiments (MTS and LDH), followed by mechanism of toxicity (ROS), and finally
8

inflammation measurements (TNF-α and IL-6). For statistical significance, at least two
to three separate experiments were done for each assay with multiple samples of each
copper nanoparticle concentration.

9

II. Literature Review
Nanotoxicity
Nanotoxicology can be defined as the “science of engineered nanodevices and
nanostructures that deals with their effects in living organisms” (Oberdörster, G., et al.,
2005:824). In regards to research on the health effects of nanomaterials, the inhalation
exposure route has been extensively studied as compared to the ingestion (via the
gastrointestinal tract) or skin absorption routes of exposure (Tsuji, et al., 2006:43). More
research is needed to determine if nanoparticles can penetrate the skin (Tsuji, et al.,
2006:44), because little information exists as to whether nanoparticles can be absorbed
through the stratum corneum (Holsapple, et al., 2005:13). Both in vivo and in vitro
studies have been conducted on the toxicology of airborne nanoparticles found in
environmental and occupational settings to include effects on the respiratory system and
extrapulmonary organs (Oberdörster, G., et al., 2005:825). Many factors contribute to
the pulmonary toxicity of nanoparticles to include size, dose to target organ or tissue,
surface coating or treatment, degree of aggregates formed, surface charge, and shape
(Tsuji, et al., 2006:47). However, Vicki L. Colvin explains in “The potential
environmental impact of engineered nanomaterials,” that, although research has focused
on the inhalation exposure route, the more common exposure route may be dermal
absorption or oral injection exposure because many nanomaterials are prepared in liquids
and agglomerate strongly, making it difficult for them to become respirable nanoparticles
(2003:1167). Also, many pulmonary studies have been conducted on ultrafine particles;
however, ultrafine particles are not identical to engineered nanoparticles. Ultrafine
10

particles are less than 100 nm in diameter, but are usually more chemically heterogeneous
and polydispersed than engineered nanoparticles (Colvin, 2003:1168).
Nanoparticles also possess the ability to produce systemic effects (Holsapple, et
al., 2005:15). One potential nanoparticle transport mechanism is via transcytosis directly
to the circulation system via the respiratory tract epithelia and interstitium (Hoet, et al.,
2004; Oberdörster, G., et al., 2005:829). Sensory nerve endings in respiratory epithelia
may also transport nanoparticles to different central nervous system structures
(Oberdörster, G., et al., 2005:829). Y. Chen and colleagues show that nanoparticles have
the ability to cross the blood-testis barrier (2003:279). Concordingly, Kim and
colleagues showed that synthesized biocompatible silica-overcoated magnetic
nanoparticles containing rhodamine B isothiocyanate (RITC) within a silica shell of
controllable thickness [MNPs@SiO2(RITC)] penetrated the blood-brain barrier and
persisted within the body for an extended period of time, but caused no toxicity
(2006:346). Nanoparticles also can produce pulmonary inflammatory mediators within
the lung that may indirectly affect the circulatory system (Hoet, et al., 2004).
Current research has focused on the cellular internalization of nanoparticles.
Recent microscopic investigations showed alveolar macrophages internalized
nanoparticles, as the particles were surrounded within the cell (Hussain, et al., 2005:982).
Macrophages isolated from the peritoneal cavity also displayed an active uptake of
functionalized carbon nanotubes (Dumortier, et al., 2006:1526). Another in vitro study
showed that nanoparticles were uptaken by J-744 macrophages via endocytosis and
ultimately degraded in the lysosomal compartment (Vauthier, et al., 2003:526-527).
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Furthermore, a different study indicated that a fullerene derivative can cross the cellular
membrane towards the mitochondria (Foley, et al., 2002:116). However, the exact
internalization mechanism is still unknown as it is difficult to determine if particle
internalization is due to a cellular or active uptake mechanism.
In Vivo Studies.
A recent in vivo experiment showed the development of dose-dependent
epitheliod granulomas and interstitial inflammation is mice after intratracheally instilled
exposure to single-wall carbon nanotubes during a 7-day and 90-day exposure (Lam, et
al., 2004:126). In the study, carbon nanotube toxicity was compared against carbon
black (CB), a known low-toxicity dust. The study displayed both carbon nanotubes and
carbon black uptake by alveolar macrophages; however, the reactions of each material
differed once in the lung. Macrophages that phagocytized the CB spread within the
alveolar space, while the macrophages containing the carbon nanotubes positioned in
centrilobular locations and formed epitheliod granulomas (Lam, et al., 2004:131). In
addition, the 90-day, carbon nanotube high-dose exposure group displayed more lesions
than the 7-day, high-dose group. One reason for this difference was the accumulation of
dust within the interstitium, which increased over time and more lesions developed.
Also, when dust entered the interstitial or subepithelial space within the lung, it could not
be removed by normal macrophage function via the mucociliary escalator system (Lam,
et al., 2004:131).
In comparison to the Lam, et al. study described above, Warheit and colleagues
used significantly higher nanoparticle concentrations. Using intratracheally instilled
12

nanontubes, the study produced results, including mortality, in approximately 15 percent
of all rats exposed to high (five mg/kg) doses of single-walled carbon nanotubes
(Warheit, et al., 2004:117). Also, the toxic effect observed was primarily due to
mechanical blocking in the upper airways of the high nanoparticle doses (Warheit, et al.,
2004:117). In addition, Warheit and colleagues reported a non-dose dependent
development of multifocal granulomas (2004:124). Warheit also points out that The
National Institute for Occupational Safety and Health (NIOSH) health risk assessments of
workplaces manufacturing single-walled carbon nanotubes showed small levels of
exposure to respirable-sized carbon nanotubes (not detectable to ≤ 0.1 mg/m3) (Maynard,
et al., 2004:106).
Another recent study examined fullerene nanoparticle (nC60) toxicity. Fullerenes
possess properties that allow consideration for use as a possible drug delivery system
(Oberdörster, E., 2004:1061). In the study, juvenile largemouth bass were exposed to 0.5
parts per million (ppm) of aqueous uncoated fullerenes for 48 hours. The study showed
that the fullerenes translocated into the largemouth bass brains via the olfactory bulb
(Oberdörster, E., 2004:1058). In addition, the largemouth bass showed lipid peroxidation
in the brain tissue and a depletion of glutathione (GSH) within its gills (Oberdörster, E.,
2004:1058).
In Vitro Studies.
Recent in vitro studies of nanoparticles have demonstrated a wide range of toxic
effects. During gameteogenesis, chemicals can have an adverse effect on germlines. One
study examined the effects of various nanoparticles on germline stem cells (C18-4).
13

Silver (Ag-15nm), molybdenum (MoO3-30nm), and aluminum (Al-30nm) nanoparticles
were tested for cytotoxicity effects to include impaired mitochondria function (MTT),
lactase dehydrogenase (LDH) leakage, and cellular apoptosis/necrosis (Braydich-Stolle,
et al., 2005). Molybdenum nanoparticles were the least toxic, displaying toxicity
properties only at significantly high dose concentrations ≥ 50 µg/mL. Silver
nanoparticles were the most toxic, with a calculated MTT Effective Concetration50 (EC50)
value of only 8.75 µg/mL and LDH EC50 value of 2.50 µg/ml (Braydich-Stolle, et al.,
2005:418). In comparison, another study using the same silver nanoparticles (Ag-15 nm)
showed a significant increase (i.e., reduced toxicity) in the MTT EC50 and LDH EC50
when using a different cell line (BRL 3A cells) (Hussain, et al., 2005:978). In the study,
LDH leakage and MTT reduction data also showed that molybdenum (MoO3-30 nm)
nanoparticles were fairly toxic and iron oxide (Fe3O4-47nm) and aluminum (Al-30 nm)
nanoparticles displayed low toxicity (Hussain et al., 2005:982). Wagner and others
showed that rat alveolar macrophage exposure to various sized aluminum nanoparticles
(50, 80, and 120 nm) showed reduced cell viability after exposures of 100 to 250 µg/mL,
while exposure to aluminum oxide nanoparticles (Al2O3) showed little toxicity
(2007:7358). In addition, the phagocytic ability of the macrophages became impaired at
only 25 µg/mL (2007:7359). Finally, as reviewed by Warheit, et al., in vitro exposure to
nano-sized C60 fullerenes produced toxicity in both human and bovine alveolar
macrophages, to include a 60 percent reduction in cell viability (2004:122).
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Reactive Oxygen Species.
Free radicals are species that have one or more unpaired electrons. Reactive
oxygen species (ROS) formation is one cause of programmed cell death, or apoptosis
(Tan, et al., 1998:1423). Oxidative stress can lead to cellular DNA damage to include
carcinogenesis initiation and progression and also mutation development (Waris and
Ahsan, 2006). Reactive species can cause lung inflammation, lipid peroxidation, and
enzyme inactivation (Martin, et al., 1997:1302). Numerous oxygen derived species can
be formed to include superoxide radical (O2-), hydrogen peroxide (H2O2), singlet oxygen
(1O2), and hydroxyl radical (·OH) (Waris and Ahsan, 2006). Each reactive species
produced has a different biological half-life influencing lethality (Sies, 1997:292).
In normal cellular and transport processes, oxidants are naturally produced as a
product of aerobic metabolism (Sies, 1997:291). Also, under normal circumstances, the
human lung lies in an equilibrium balance between oxidant and defensive enzymatic and
nonenzymatic antioxidant production (Dörger, et al., 1997:1311). Many mediators
released by alveolar macrophages target specific cell receptors; however, ROS are nonspecific and can cause significant tissue damage and injury (Morgan and Shines,
2004:139), especially if produced at higher rates (Sies, 1997:291). In addition, the
formation of reactive species leads to the activation of signal transduction pathways and
acts as secondary messengers in other cellular pathways (Martin, et al., 1997:1301;
Forman and Torres, 2001:189).
Nanoparticles can induce ROS formation and have shown a greater inflammatory
potential than larger particles (Oberdörster, G., et al., 2005:826-827). ROS production
15

mechanisms include the metabolism of nanoparticles to produce redox active
intermediates (Oberdörster, G., et al., 2005:828). Another mechanism of ROS
production is by the activation and release of NADPH oxidase by alveolar macrophages
(Forman and Torres, 2001:189). Attempted phagocytosis can lead to free radical
production. An in vitro study of vitreous fibers showed that the longer in time the
attempted phagocytosis, the greater the amount of ROS created by alveolar macrophages
(Dörger, et al., 2001a:212).
In the in vitro study using BRL 3A cells described above, Ag (15 and 100 nm)
nanoparticles produced ROS; thus, the degree of oxidative stress is believed to be one of
the primary contributors to nanoparticle cytotoxicity (Hussain, et al., 2005:982).
Measures of oxidative stress include a depletion of reduced GSH or an increase in
oxidized GSH (Hussain and Frazier, 2002:424). GSH is a molecule that plays a role in
cellular oxidation-reduction homeostasis (Sies, 1999:916). The depletion of GSH is a
good indicator of decreasing antioxidant defenses against reactive oxygen species
(Oberdörster, E., 2004:1061). Hussain and colleagues noted that an increase in ROS
production correlated with a decrease in GSH, confirming the mechanism of GSH
depletion leading to a weakened defense against ROS. Another study showed that an
initial ROS increase (5 to 10 fold) is due to a depletion of GSH, while a secondary
increase (200 to 400 fold) can be attributed to the mitochondrial electron transport chain
(Tan, et al., 1998:1423). In the study by Tan and colleagues, a gradual ROS increase was
observed during the first six hours, followed by a dramatic increase over the following
six hours. The initial, gradual ROS increase lasted until GSH levels fell below 20
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percent. After the antioxidant cysteine and GSH depletion, ROS levels increased
substantially and at a much faster rate (1998:1429).
Copper
Copper (Cu) is a metal used in numerous applications to include in conductors to
distribute electricity and heat. Copper pipes are also used to transport drinking water
throughout water distribution systems. Copper normally exists in various states including
oxidized cupric (Cu2+), reduced cuprous (Cu+), and metallic copper (0) (Linder and
Hazegh-Azam, 1996:797S). In most biological systems, the cupric form is most
prevalent (Linder and Hazegh-Azam, 1996:797S). Cupric compounds are blue-green in
color and highly soluble in water (Barceloux, 1999:219). In aqueous solutions, cuprous
ions commonly dissociate to cupric (II) and metallic copper (Barceloux, 1999:219).
Copper is used, as either a metal or an alloy, in machinery, construction, and
transportation (Barceloux, 1999:219). Copper is also used in such applications as
jewelry, electrical applications, fabrication of dental crowns, dye manufacturing,
petroleum refining, metal finishing, and wood preservation (Barceloux, 1999:219). Not
only is copper used for production purposes, but the human body utilizes it as well.
Copper is an essential trace element for humans. Normal copper intake levels
typically range from 0.6 to 1.6 mg/day with a recommended dietary allowance of 0.9
mg/day (Dietary Reference). However, the contamination of food and water by excess
copper can cause severe acute gastrointestinal illnesses (Barceloux, 1999:218). Copper
can also be found in drinking water distribution systems, with an established action level
of 1.3 mg/L as measured at the 90 percentile limit (US EPA Copper). In surface water
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sources, copper concentrations average 10 parts per billion (ppb), while averaging only 5
ppb in groundwater (Dorsey, et al., 2004). Copper is found in the atmosphere as a result
of natural and anthropogenic sources at a concentration range of 5-200 ng/m3 (Dorsey, et
al., 2004). The American Conference of Governmental and Industrial Hygienists
(ACGIH) Threshold Limit Value-Time-Weighted Average (TLV-TWA) is 0.2 mg/m3 for
copper fumes and 0.1 mg/m3 for copper dusts and mists as pertaining to occupational
exposures (ACGIH TLV Guide, 2006). Copper is a respiratory irritant to the mouth,
eyes, and nose. However, copper metal fumes are rarely produced due to the required
high temperatures that are rarely met in normal industrial operations (Barceloux,
1999:225). The International Agency for Research on Cancer or the United States
Toxicology Program lists copper as a suspected human or animal carcinogen (Barceloux,
1999:225). Thus, it is important to understand how the human body processes copper.
The human body has natural mechanisms to control cellular uptake, elimination
and distribution of copper (Bertinato and L'Abbé, 2004:316). The small intestine serves
as the major site of copper absorption and regulation for the human body (Bertinato and
L'Abbé, 2004:317). However, the liver serves as the initial site of copper deposition;
thus, the liver commonly is the target organ for cytotoxic effects (Gaetke and Chow,
2003:149). Copper is normally attached to proteins in the liver (Seth, et al., 2004:501).
These proteins, known as copper chaperones, deliver copper to specific targets within a
cell (Bertinato and L'Abbé, 2004:316). These same copper chaperones that exist in
humans have also been identified in lower eukaryotic organisms (Bertinato and L'Abbé,
2004:316).
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A deficiency or excess in copper levels can have detrimental effects on the body.
A copper deficiency can lead to Menke’s syndrome while a copper overload can cause
Wilson’s disease (Bertinato and L'Abbé, 2004:317). Menke’s syndrome is often fatal
during the early childhood years (Gaetke and Chow, 2003:149) and is primarily caused
by an inability to transfer copper into the blood from intestinal mucosal cells (Linder and
Hazegh-Azam, 1996:799S). Wilson’s disease is a genetic disorder that causes ineffective
copper metabolism leading to cytotoxic effects and an accumulation of copper in
hepatocytes (Seth, et al., 2004:501-502). In addition, copper overload can effectively
lead to the depletion of GSH and increased cellular toxicity. One mechanism to combat
cellular toxicity is by the transfer of excess copper to metallothionein (MT) (Freedman, et
al., 1989:5603). Metallothioneins normally function to store extra copper and other
metal ions and play a role in detoxifying copper (Linder and Hazegh-Azam, 1996:803S).
Even though some levels of copper are required for proper antioxidant defense,
copper also leads to the production of reactive oxygen species (Gaetke and Chow,
2003:158). The formation of reactive species is considered the primary mechanism of
copper toxicity. Studies show copper can act as a catalyst in ROS production, which can
ultimately lead to oxidative stress and lipid peroxidative damage (Stohs and Bagchi,
1995:321). Both forms of copper ions participate in redox reactions, with the amount of
ROS produced related to the quantity of free copper ions (Gaetke and Chow, 2003:150).
As mentioned previously, copper ions are normally bound to proteins. However, copper
ions that become free and accumulate can lead to the formation of reactive hydroxyl
radicals (Gaetke and Chow, 2003:147). If reducing agents such as superoxide (*O2),
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ascorbic acid, or GSH are present, Cu2+ can be reduced to Cu+. The Cu+ then can
catalyze the reaction of hydrogen peroxide to the formation of hydroxyl radicals (OH+)
via the Haber-Weiss Reaction (see Figure 1, below) (Gaetke and Chow, 2003:150). As
reviewed by Gaetke and Chow, the hydroxyl radicals are one of the most powerful
oxidizing radicals and can react with almost any biological molecule (2003:150) and
subsequently affect proteins, lipids, and nucleic acids (Halliwell and Gutteridge, 1984:2).
O2· - + Cu2+ → O2 + Cu+
Cu + H2O2 → Cu2+ + OH- + OH·
+

Figure 2: Haber-Weiss Reaction (Brember, 1998:1071S)
Other toxicity studies have also demonstrated the effects of copper. Rats exposed
via bronchoalveolar lavage (BAL) to equal doses of six different metals showed copper
to be the most toxic, as copper was the first metal to produce pulmonary inflammation
(Rice, et al., 2001:52). The copper exposed rats also had the highest lactate
dehydrogenase (indicating membrane leakage and cellular death) and protein levels. In
addition, at the low exposure dose, only copper produced neutrophilia in significant
levels and at the high exposure dose, copper was the only metal to produce macrophage
inflammatory protein (MIP-2) mRNA at the four-hour exposure point, indicating copper
to be the most pro-inflammatory metal studied (Rice, et al., 2001:46 and 50). An in vitro
study of a human hepatoma cell line (Hep G2) showed the cellular membrane and
mitochondria resistant to copper exposure, while the lysosomes interacted with the
copper and were very susceptible to damage (Seth, et al., 2004:501). Also, cell viability
was reduced the greatest (only 14 to 25 percent viability) after exposure to copper dental
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alloys, as compared to other metals such as nickel, zinc, palladium, tin, and indium
(Schmalz, et al., 1998:1693).
Copper Nanoparticles
Copper nanoparticles are used for many different industrial applications. Current
usage includes lubricants, polymers, plastics, and metallic coatings and inks (Chen, Z., et
al., 2006:110). Copper nanoparticles possess superior mending effects (Liu, G., et al.,
2004:abstract). One study showed copper nanoparticles effectively decreased wear and
friction and mended worn surfaces when used as oil additive (Tarasov, et al., 2002:69).
Copper nanoparticles have also been used as a bimetallic catalyst on activated carbon
effectively reducing elevated levels of nitrate in water (Barrabes, et al., 2006:84). Chen
and Hong showed that the addition of 15 or 30 nm copper nanoparticles greatly increased
the ductility of diamond-like carbon (DLC) nanocomposite films (2005:269). Copper
nanoparticles have also been used in electrically conductive polymer composites as fillers
(Zhang, et al., 2007). Also, the varying uses for copper nanoparticles extend beyond
industrial applications.
Copper already is known as an effective antibacterial agent due to its ability to
combine with the –SH enzyme group and lead to protein inactivation (Yoon, et al.,
2007:572). One recent study evaluated the use of copper nanoparticles (100 nm) as
antibacterial agents against Escherichia coli and Bacillus subtilis. The B. subtilis showed
the greatest susceptibly when exposed to the copper nanoparticles; 31.37 µg/mL of
copper nanoparticles degraded 90 percent of the B. subtilis, while 40.11 µg/mL was
required to degrade the same percentage of E. coli (Yoon, et al., 2007:572 and 574). In
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addition, copper-fluoropolymer (Cu-CFx) nano-composite films layers have been
effectively utilized as a bioactive coating to inhibit microorganism growth to include E.
coli, Lysteria, and Staphylococcus aureus (Cioffi, et al., 2005:607).
Different methods of producing copper nanoparticles have been utilized.
Techniques used to create copper nanoparticles include the solvated metal atom
dispersion (SMAD) technique (Ponce and Klabunde, 2005:1). Copper nanoparticles have
also been plated on carbon nanotubes using an electroless plating method (Xu, et al.,
2004:1499). Copper nanoparticles commonly possess a surface coating. If the particle
does not contain a surface coating, it will most likely become oxidized when exposed to
air. Athanassiou and colleagues discovered that copper nanoparticles with a carbon
coating could be produced at up to 10 grams/hour by the use of a modified flame spray
synthesis and under reducing conditions (2006:1668). Li and others sprayed copper
nanoparticles with carbon-and-hydrogen (CH) plasma produced from a hollow-cathode
glow discharge (HCGD) (Li, C., et al., 2004:1866).
As stated, there has been few toxicity studies conducted on copper nanoparticles.
However, one recent in vivo study examined the toxicity effects of copper particles
(micro-sized (17 µm) and nano-sized (23.5 nm)) by oral gavage in mice (Chen, Z., et al.,
2006:111). As mentioned previously, the surface area of nanoparticles are significantly
greater than larger counterparts. As determined by the use of atomic force microscopy,
the copper nanoparticles surface area was 295,000 cm2/g as compared to 399 cm2/g for
the microsized copper particles (Chen, Z., et al., 2006:111). However, one potential
limitation of nanoparticle toxicity studies is the tendency for nanoparticles to
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agglomerate, which leads to the formation of larger (i.e., micro-sized) particles, in which
nanoparticles are then not effectively studied. To ensure limited agglomeration, Chen
and colleagues ensured all mice were dosed within 20 minutes of nanoparticle
preparation to ensure minimal agglomeration (2006:110). In the study, mice were
exposed to copper nanoparticle doses of 108 to 1080 mg/kg, while the micro-copper
doses where significantly higher (i.e., >5,000 mg/kg) (Chen, Z., et al., 2006:111). The
determined lethal dose-50 (LD50) for the copper nanoparticles was 413 mg/kg
(moderately toxic classification on the Hodge and Sterner Scale) while the micro-copper
LD50 was significantly higher at >5,000 mg/kg (non-toxic classification on the Hodge and
Sterner Scale) (Chen, Z., et al., 2006:112). In addition, the copper nanoparticles
displayed a dose-dependency degradation of the renal proximal tubular cells within the
kidney of the mice (Chen, Z., et al., 2006:114). In addition to the kidney, the established
target organs included the liver and the spleen (Chen, Z., et al., 2006:109). The spleen as
a target organ is important because of the vital role it plays in both the lymphatic and
immune system.
An associated study by Meng and colleagues examined the reaction of both
micro-and-nano copper particles. The study, “Ultrahigh Reactivity and Grave
Nanotoxicity of Copper Nanoparticles,” showed that copper nanoparticles deposited into
renal tissues more efficiently than the micron sized copper particles (Meng, et al.,
2007:596). Once inside the kidney, the copper nanoparticles are extremely active and
showed a tendency to react with the gastric juice and be converted by the hydrochloric
acid to the more toxic cupric ions with an associated increase in pH (Meng, et al.,
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2007:596). Copper nanoparticles are also toxic to non-mammalian toxicity models, as
shown in “Exposure to Copper Nanoparticles Causes Gill Injury and Acute Lethality in
Zebrafish (Danio rerio).” 80 nm copper nanoparticles displayed a 48-hour Lethal
Concentration50 (LC50) of only 1.5 mg/L, as the gill was the primary target organ
(Griffitt, et al., 2007).
Respiratory System
The human respiratory system is one of the few organ systems in the human body
in constant contact with the environment. The respiratory system consists of two main
sections; the conducting airways and the alveoli. The conducting airways move air inand-out of the lungs, while the alveoli are responsible for carbon dioxide and oxygen gas
exchange with the capillaries. The human lung contains on the order of 300 million
alveoli within the deepest portion of the lung making the alveoli extremely susceptible to
environmental contaminants because of their large surface area. In general, the smaller a
particle is, the deeper the penetration within the human lung. Thus, the small size of
nanoparticles makes them extremely effective in reaching the alveoli of the respiratory
system (Hoet, et al., 2004). The International Commission of Respiratory Protection
Task Group states that 30 percent of 3 µm particles can reach the lung while 55 percent
of 0.05 µm particles can (Bates, et al., 1966).
Macrophages.
Macrophages are located throughout the entire human body and aid in the defense
against various pathogens. Macrophages, which can be stationary or mobile within an
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organ system, are terminally differentiated monocytes that are part of the non-specific, or
innate immune system and are normally located in connective tissue. As part of the
initial response within the immune system, macrophages play a key role in phagocytosis
of particulates. However, macrophages also play a key role in the specific immune
system as antigen presenting factors for lymphocytes. Other responsibilities of
macrophages include particle clearance and the recruitment and activation of other
inflammatory cells (Dörger and Krombach, 2002:47).
Macrophages serve as the first line of defense and have the ability to migrate to
sites of injury or inflammation. If successful, macrophages will phagocytize and
eliminate pathogens and other foreign materials. However, if unsuccessful, an associated
inflammatory response can result in swelling and tissue injury (Laskin and Laskin,
2001:112). In addition, macrophages are secretory cells that are able to produce
proinflammtory and cytotoxic mediators to include reactive oxygen species (Laskin and
Laskin, 2001:111). Phagocytosis attempts can also lead to the activation of signal
transduction factors to produce various cytokines, growth factors, and eicosanoids
(Dörger and Krombach, 2002:50).
There are different types of macrophages that exist within the respiratory system
to include alveolar, peritoneal, and pleural macrophages. However, important differences
between the macrophages exist (Dörger, et al., 2001a:208). In the respiratory system,
alveolar macrophages can be considered the primary phagocytes as they serve as a first
line of defense against inhaled particulates. Alveolar macrophages exist between the air
and lung interface and are located within the alveolus and on the epithelial surface in the
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alveolar surfactant film (Lehnert, 1992:17; Gardner, 1984; Dörger, et al., 2001b:65).
Alveolar macrophages are highly mobile cells and are the only aerobically exposed
macrophages (Paine III, et al., 2001:L1210; Dörger and Krombach, 2002:47). Alveolar
macrophages are also more likely to respond to a pathogen if complement factors are
present. For example, one study, reviewed by Dörger and Krombach, showed asbestos
fibers triggered the formation of the chemoattractant C5a, which increased alveolar
macrophage response (2002:48).
Macrophages of various species are used for in vitro studies, with many showing
differences in response. For example, mouse macrophages are more sensitive to metal
ions from dental biomaterials than are human macrophages (Wataha, et al., 1995:243).
Rat alveolar macrophages are used in many in vitro toxicity studies to measure the
cytotoxic effects of various chemicals and particulates; thus, the differences between
human and rat alveolar macrophages must be examined. The clearance rate for human
and rat alveolar macrophages differ; the clearance rate for human macrophages is an
order of magnitude lower than rat alveolar macrophages, as reviewed by Dörger and
Krombach (2002:48). However, larger alveolar macrophages are able to phagocytize and
remove larger, longer particulates and fibers and a study by Krombach and colleagues
showed that human alveolar macrophages were larger than rat alveolar macrophages.
Using selective flow cytometric analysis of cell volume, human alveolar macrophages
were > 21 µm in comparison to 13 µm for rat alveolar macrophages (1997:1261). Also, a
difference in cellular products exists between human and rat alveolar macrophages. One
in vitro study showed the inability of human alveolar macrophages to produce inducible
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nitric oxide synthase (iNOS) and nitric oxide (NO) when stimulated with
lipopolysacchardie (LPS) and/or interferon-γ (IFN- γ), while rat alveolar macrophages
were able to produce iNOS (Jesch, et al., 1997:1297).
After a particulate is introduced into the alveolar space, alveolar macrophages
attempt to engulf the particulate and produce inflammatory mediators. The normal
clearance mechanism for particulates, termed the mucociliary escalator, is via the trachea
and subsequently cleared in the esophagus (Lam, et al., 2004:131). However, various
situations exist in which macrophages are unable to successfully clear all particles by the
normal pathway. One difficulty is the extremely small size of the particles and increased
quantity of particles. If particles are too small, the macrophages may not effectively
locate the particles for attempted phagocytosis (Renwick, et al., 2001:124). In addition,
too many particles for a macrophage to successfully clear is termed overload (Lehnert,
1992). If macrophages do experience particle overload, the particles may interact with
epithelial cells and cross the interstitial membrane (interstitialization) after which the
particles can no longer be cleared by the normal pathways (Donaldson, et al., 1998:553554; Oberdörster, G., et al., 1992:196-198). As reviewed by Bermundez, et al.,
prolonged overload can even lead to the formation of pulmonary tumors in rats
(2004:354). Impaired macrophage mobility and toxicity to the macrophage are other
factors in unsuccessful particle clearance (Donaldson, et al., 1998:554). An in vivo study
of rats showed reduced clearance of particles due to macrophage damage after exposure
to various doses of titanium dioxide (TiO2)(5, 50, and 250 mg/m3) (Warheit, et al.,
1997:10).
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As mentioned previously, nanoparticles possess increased surface areas as
compared to larger counterparts. As reviewed by Donaldson, et al., using particle
volume as the main indicator, macrophage clearance typically becomes impaired at 60
µm3 particle/macrophage (i.e., six percent of a typical macrophage volume) based on the
assumption that all particles in the lung are evenly distributed (1998). However, the
particle surface area has shown to be a more important factor than particle volume in
impaired macrophage clearance (Oberdörster, G., et al., 1994:178). One study of
ultrafine particles showed a slower clearance rate, increased retention time, and an
increased transport to the pulmonary interstitium as compared to fine particles
(Oberdörster, G., et al., 1994:178). Macrophage clearance of ultrafine particles (titanium
dioxide (20 nm)) became impaired at only 2.6 percent of macrophage volume and caused
the clearance half-time to increase eightfold, as compared to fine titanium dioxide (250
nm) (Oberdörster, G., et al., 1994:177).
Cytokines
Cytokines are peptides, proteins, or glycoproteins that actively play a role in
intracellular signaling (Bondeson, 1997:131). The body produces various cytokines that
are an integral part of the human immune system, but also those that regulate
inflammation, apoptosis, and hematopoesis and promote cellular growth (House,
2001:abstract). Many cytokines control multiple actions within the body. Cytokines
normally act on a local level and are removed from the blood circulation rather quickly
(House, 1999:18). There is also great redundancy within the human body as different
cytokines perform the same function (House, 1999:18). For example, TNF and IL-6 may
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be similar, but each bind to different receptors, as receptors can be either membranebound or soluble molecules (House, 1999:18 and 20). Cytokine production and the
inflammation response of the immune system typically involve alveolar macrophages.
The inflammatory response is a natural defense mechanism of the human body against
foreign particulate matter. However, increased and prolonged inflammation can cause
significant damage. Two proinflammatory cytokines, both secreted by alveolar
macrophages, are TNF-α and IL-6.
Tumor Necrosis Factor-α.
TNF-α acts through both autocrine and paracrine pathways to stimulate the
release of other cytokines that play a key role in the inflammatory response by recruiting
and activating various inflammatory species, including neutrophils (Driscoll, et al.,
1997:1159). TNF-α also plays a cytotoxic role against some tumor cells in vivo
(Feliciani, et al., 1996:302). ROS production is stimulated by TNF-α which also depletes
cellular GSH (Mukhopadhyay, et al., 2006). TNF-α stimulates inflammatory species to
release IL-6 (Laskin and Laskin, 2001:115), and stimulates IL-6 itself (Driscoll, et al.,
1997:1159). Macrophages rapidly produce TNF-α when inflammatory stimuli are
present (Laskin and Laskin, 2001:114). Overall, TNF-α acts as a protective factor in
smaller doses, but plays a role as a hepatotoxic in larger doses (Laskin and Laskin,
2001:115).
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Interleukin-6.
IL-6 stimulates the hepatic synthesis of acute-phase plasma proteins and also Bcells (Feliciani, et al., 1996:302). IL-6 is a proinflammatory mediator in the chronic
inflammation response (i.e., strengthens the effects of other proinflammatory cytokines
such as IL-1 and TNF-α), but also an anti-inflammatory agent during the acute response
(Rubin, et al., 2007; Bondeson, 1997:131; Lemaire and Ouellet, 1996:475).
TNF-α and IL-6 Studies.
As reviewed by Driscoll et al., in vitro alveolar macrophage studies showed TNFα production after exposure to various contaminants such as quartz, crocidolite and
chrysotile, and coal dust (1997:1159). Copper coated titanium disks showed an increase
in TNF-α production in vivo in rats up to 24 hours (Suska, et al., 2003:465). One study
attempted to study the interactions of non-nano size zinc (ZnCl2) and iron (FeCl3) with
nanoparticle carbon black. The relationship between ZnCl2 and the nanoparticles
produced a synergistic effect in the production of TNF-α, while FeCl3 and nanoparticle
carbon black did not (Wilson, et al., 2007:88). An in vitro study of peritoneal cavity
macrophages showed non-soluble functionalized carbon nanotubes produced TNF-α and
IL-6, while soluble functionalized carbon nanotubes did not (Dumortier, et al.,
2006:1526). Also, exposure to chitosan-DNA nanoparticles in a human THP-1
macrophage cell line did not induce TNF-α or IL-6 production (Chellat, et al.,
2005:7265). One study discovered an increased release of IL-6 and an accompanying
inflammatory response when exposed to asbestos fibers (Lemaire, et al., 1996:475). In
addition, as reviewed by Warheit, et al., both human and bovine alveolar macrophages
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produced increased IL-6 levels after in vitro exposure to nano-sized C60 fullerenes
(2004:122).
Cellular Assays
MTS Assay.
Mitochondria play a critical role in cellular functions by aerobic adenosine
triphosphate (ATP) production (Hussain and Frazier, 2002:430). The MTS assay
(Promega CellTiter 96 AQueous One Solution Cell Proliferation Assay) uses a tetrazolium
compound ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, inner salt; MTS(a)]) and an electron coupling reagent
(phenazine ethosulfate; PES) to measure cell viability. The assay measures cell viability
when the tetrazolium compound is bioreduced by viable cells to a colored formazan
product (see Figure 3, below). The conversion in viable cells is done by nicotinamide
adenine dinucleotide phosphate (NADPH) or nicotinamide adenine dinucleotide (reduced
form) (NADH) produced by dehydrogenase enzymes. The formazan product is measured
at 490 nm absorbance and is relative to the number of viable cells (CellTiter 96 AQueous
One Solution Cell Proliferation Assay Technical Bulletin).
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Figure 3. Chemical structure of MTS and the converted product of Formazan, which is a
measure of cell viability (CellTiter 96 AQueous One Solution Cell Proliferation Assay
Technical Bulletin)
LDH Assay.
The CytoTox-ONETM Assay evaluates the degree of damaged cellular membrane
by measuring the amount of the enzyme lactate dehydrogenase (LDH) via a fluorescent
measurement. As depicted in Figure 4 below, resorufin is measured after lactate, NAD+,
and resazurin are supplied as substrates (CytoTox-ONETM Homogenous Membrane
Integrity Assay Technical Bulletin).

Figure 4. LDH Chemical Reaction (CytoTox-ONETM Homogenous Membrane Integrity
Assay Technical Bulletin)
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ROS Assay.
The ROS procedure uses a 2’,7’-dichlorofluorescein diacetate (DCFH-DA) probe.
When applied to intact cells, DCFH-DA is enzymatically hydrolyzed to nonfluorescent
DCFH or oxidized to dichlorofluorescein (DCF) if ROS are present. The DCF is then
measured to approximate the degree of oxidative stress caused by ROS (Wang and
Joseph, 1999:612-613).
Cytokine Assay.
An enzyme-linked immunosorbent assay (ELISA) is an immunoassay used to
measure cytokine production. ELISA uses solid-phase antibodies able to extract a
specific cytokine from a sample (i.e., cell culture supernatant). Another antibody is then
used to convert a substrate to a colorimetric end product that can be measured by a plate
reader (House, 2001:54).
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III. Methodology
Overview
The methodology involved rat alveolar macrophages as the cell line for all in vitro
toxicity and cytokine experiments. The progression of assays started with basic toxicity
experiments (MTS and LDH), followed by mechanism of toxicity (ROS), and finally
inflammation measurements (TNF-α and IL-6). For statistical significance, at least two
to three separate experiments were done for each assay with multiple samples of each
copper nanoparticle concentration. In addition, detailed experimental procedures are
located in Appendices A through E.
Cell Culture
Frozen alveolar rat (Rattus norvegicus) macrophages were acquired from the
American Type Culture Collection (ATCC). The cell line (ATCC Number: CRL-2192
and Designation NR8383) was initially isolated by lung lavage in August 1983. Some
cellular products of the alveolar macrophages include transforming growth factor beta
(TGF beta), interleukin 1 (IL-1), and interleukin 6 (IL-6) (ATCC).
F12K Medium Kaighn’s Modification of Ham’s F-12 with L-glutamine was used
as the primary growth media. In addition, 20 percent fetal bovine serum (FBS) and one
percent Penicillin/Streptomycin were added to the media. The growth media was stored
at four degrees Celsius. Exposure media used included the above mentioned media and
one percent Penicillin/Streptomycin, but only ten percent FBS.
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Alveolar macrophages were maintained in 75 cm2 plastic culture flasks (Corning
Incorporated). Cell flasks were kept in an incubator at 37 degrees Celsius and five
percent carbon dioxide (Thermo Electron Corporation Forma Series II Water Jacketed
CO2 Incubator). Macrophages were split into new culture flasks upon approaching a
confluence of 50 percent. Cultures were maintained by scraping adherent cells with a
plastic scraper (FisherBrand Disposable Cell Scraper) and then transferring cells to new
culture flasks and periodically adding new growth media to the flasks.
Nanoparticle Solutions
Copper nanoparticles (40, 60, and 80 nm) were obtained from NovaCentrix
(formerly Nanotechnologies, Inc.). Nanoparticle solutions were made by weighing out
approximately two to four milligrams of nanoparticles on a balance (Denver Instrument
Company) in a glass vial. Cadmium oxide particles (Fluka Chemicals, Sigma-Aldrich
Corporation) were used as a positive control in the MTS assay, due to its highly toxic
properties as shown in previous studies (Hussain, et al., 2005). Sterile millipore water
was then added to the glass vial to make a one mg/mL stock solution for each size of
copper nanoparticle. Each respective nanoparticle stock solution was then sonicated
(Cole Palmer Instrument Co. Ultrasonic Homogenizer) for approximately 20 seconds to
ensure proper particle suspension in solution and to reduce particle agglomeration. After
sonication, each stock solution was used to make different doses (0 (just exposure
media), 1, 2.5, 5, 7.5, and 10 µg/mL) of each respective copper nanoparticle (40, 60, and
80 nm) by dilution with the above described exposure media.
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Experiment Overview
Each experiment included the following procedures: cell counting, cell plating,
nanoparticle dosing, and the respective cellular assay. In total, five assays were
performed, in order: MTS, LDH, ROS, TNF-α, and IL-6. The MTS assay was performed
first to determine the appropriate particle concentrations that were toxic to alveolar
macrophages.
Cell Counting.
Alveolar macrophages were counted before each experiment to ensure sufficient
cells were available for each respective assay. Cells obtained from culture flasks were
placed in 50 mL conical tubes and inverted twice to ensure adequate mixing of the cell
suspension. 10 µL of cell suspension was then placed on a hemacytometer with a glass
cover slip and placed under a microscope (Nikon Phase Contrast ELWD 0.3). The
hemacytometer displays four equally sized quadrants that each contained 16 squares.
Only cells within, on top, and to the left of each square were counted (i.e., cells on the
right and bottom perimeter of each square were not counted). All cells were counted in
each respective quadrant and then averaged over the four quadrants.
Cell Plating.
After cell counting, alveolar macrophages were plated at approximately 250,000
cells/mL in a 96-well clear bottom plate (Corning Incorporated Costar). Appropriate
dilutions (i.e., C1V1 = C2V2 ) were performed using the cell suspension and growth
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media. After the cells were plated, the 96-well plate was placed in the incubator (at
conditions stated above) for 24 hours.
Nanoparticle Dosing.
After removing the 96-well plate from the incubator at the 24-hour time point, the
growth media was aspirated (cells were adhered to the well bottom). Nanoparticle dosing
solutions (prepared as described above in Nanoparticle Solutions) were vortexed (Fisher
Scientific/Fixed Speed Mini Vortexer) for approximately five seconds directly before
being added to each respective well to ensure a homogenous nanoparticle solution. The
appropriate nanoparticle dosing solution (200 µL) was then added to each respective well
in the 96-well plate and subsequently incubated for an additional 24 hours. As mentioned
previously, as described by Z. Chen, et al. (2006), an effort was made to dose cells as
rapidly as possible after sonicating, making dosing concentrations, and vortexing, to
ensure minimal agglomeration of nanoparticles. Doses used included 1, 2.5 5, 7.5 and 10
µg/mL, depending on the specific experiment.
Cellular Assays
MTS Assay.
Following the procedures of Braydich-Stolle, et al. (2005), after incubation of
dosed cells for 24 hours (see Figure 5, below), the exposure media containing the
nanoparticle solutions were aspirated (cells were still adherent to the well bottom) and
each well was rinsed three times with 200 µL of one percent phosphate buffered saline
(PBS) (Invitrogen Corporation/10х Gibco Phosphate Buffered Saline, 7.2). 100 µL of
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exposure media was then added to each well, followed by 20 µL of tetrazolium
compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium, inner salt; MTS(a)] (Promega CellTiter 96 AQueous One Solution Cell
Proliferation Assay). The plate was then lightly tapped to ensure adequate mixing of the
reagent within the cells attached to the plate. After a four hours incubation period at 37
degrees Celsius and five percent carbon dioxide, the plate was read on the Molecular
Devices Spectra Max 190 plate reader at a wavelength of 490 nm. Three independent
experiments were conducted with at least two separate samples (for each dosed
concentration) for each experiment. The relative cell viability (%) results were computed
by dividing the absorbance values from wells with dosed cells by the absorbance values
from the control wells (i.e., wells with only macrophages and no nanoparticles). The two
or more separate sample values were averaged as the mean of each independent
experiment. The means of the three independent experiments values were subsequently
taken as the overall relative cell viability (%).
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24 Hours
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Nanoparticles
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MTS or LDH
Assay

Figure 5. MTS/LDH assay procedures
LDH Assay.
Following the procedures of Braydich-Stolle, et al. (2005), the LDH assay
(Promega CytoTox-ONETM Homogenous Membrane Integrity Assay) was accomplished
in conjunction with the above mentioned MTS assay. After incubation of dosed cells for
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24 hours (see Figure 5, above), 50 µL of the supernatant from the 200 µL nanoparticle
solution used for dosing was removed and placed in a new 96-well plate (50 µL of a
positive control was also added to empty wells). 50 µL of reagent (CytoTox-ONETM)
was then added to each well. The plate was then lightly shaken for approximately 30
seconds. This plate was incubated in the dark for 10 minutes at room temperature.
Afterwards, 25 µL of stop solution was placed in each well and the plate was
subsequently shaken for about 10 seconds. In addition, the plate was kept out of the
direct light. Immediately following the stop solution addition, the fluorescent signal was
measured in the Molecular Devices Spectra Max Gemini XS microplate reader, with an
excitation wavelength of 560 nm and read at a wavelength of 590 nm. Three independent
experiments were conducted with at least three separate samples (for each dosed
concentration) for each experiment. The LDH leakage (%) results were computed by
dividing the absorbance values from wells with dosed cells by the absorbance values
from the control wells (i.e., wells with only macrophages and no nanoparticles). The
three or more separate sample values were averaged as the mean of each independent
experiment. The means of the three independent experiments values were subsequently
taken as the overall relative cell viability (%).
Time Study.
After toxic effects were observed at the 24-hour time point, a time study using the
MTS assay procedure described above was done with Cu-80 nanoparticles to determine
cytotoxic effects at earlier time points (see Figure 6, below). The only difference was in
the dosed cells incubation time. For the MTS assay described above, the incubation time
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was 24 hours; however, during the time study, incubation times of dosed cells included
one-, two-, three-, four-, six-, and eight-hour time intervals. One independent time study
experiment was conducted with at least four separate samples for each dosed
concentration. The four or more separate sample values were averaged as the mean of
each independent experiment. The relative cell viability (%) results were computed by
dividing the absorbance values from wells with dosed cells by the absorbance values
from the control wells (i.e., wells with only macrophages and no nanoparticles). As only
one separate experiment was conducted, the associated error was represented as the
standard deviation of the four or more separate samples (as compared to the standard
deviation of the means of each independent experiment as described in the MTS and
LDH section). Thus, each dosed concentration had some associated error, as did the
control.
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Figure 6. Time study procedures
ROS Assay.
Procedures were followed as described in Wang and Joseph (1999), only with
minor modifications. For the ROS assay, a black bottom 96-well plate was used for the
initial cell dosing, instead of a clear plate. After the 24-hour cell plating period, the
growth media was removed and 200 µL of 100 µM dichlorofluorescin diacetate (DCFHDA) probe was added to each well. The plate was then incubated at 37 degrees Celsius
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and five percent carbon dioxide for 30 minutes. After the 30 minute incubation, the
DFCH-DA probe was removed from each well and 200 µL of each respective
nanoparticle solution was added to each well. In addition, a positive control of different
molar strength (i.e., 100 to 2000 µM) hydrogen peroxide was used. The plate was then
covered with aluminum foil and placed in the above mentioned incubator for different
time exposures (i.e., 6 and 24 hours). At the 6-and-24 hour time points, the fluorescent
signal was measured on the Molecular Devices Spectra Max Gemini XS microplate
reader, with an excitation wavelength of 485 nm and read at a wavelength of 530 nm.
During the entire assay procedure, all plates were treated in a dark room with only a
fluorescent red light. Three independent experiments were conducted with at least three
separate samples (for each dosed concentration) for each experiment. The ROS results
were computed by dividing the fluorescent values from wells with dosed cells by the
fluorescent values from the control wells (i.e., wells with only macrophages and no
nanoparticles). The three or more separate sample values were averaged as the mean of
each independent experiment. The means of the three independent experiments values
were subsequently taken as the overall ROS fold of increase.
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Figure 7. ROS procedures
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Read at 6 or
24 Hours

TNF-α Assay.
The TNF-α Assay (R&D Systems, Inc. Catalog Number:DY510) was broken up
into two separate steps. The first step was the ELISA plate preparation with the capture
antibody. The second step consisted of adding a supernatant sample from a dosed plate
to the prepared plate for determination of TNF-α production. The dosed plate was done
as described in previous sections; however, a TNF-α stimulant was also used. The
cellular activator used was E. coli lipopolysaccharide (LPS) (Sigma-Aldrich). House
explains that for macrophages, the best cellular activator to use is LPS (1999:22). To
determine what concentration was needed to stimulate TNF-α, a plate of LPS-dosed cells
was done (i.e., no particles) before the actual experiment involving copper nanoparticles
began.
To prepare the plate (Greiner Microlon LE High Binding Plates) during the first
step, 100 µL of capture antibody (720 µg/mL of mouse anti-rat TNF-α reconstituted with
1.0 mL of PBS) was used to coat each well in a 96-well plate. After a 24-hour incubation
period at room temperature, the capture antibody was aspirated and each well was
washed with approximately 300 µL of wash buffer (Biosource 25x Wash Buffer) three
times. The plates were then blocked by the addition of 300 µL of reagent diluent (one
percent BSA (Calbiochem) in PBS) to each well. The plate was incubated at room
temperature for one hour. After the one hour, the reagent diluent was aspirated and each
well was washed as described above with the wash buffer. This concluded the first step
of plate preparation.

42

After the plate was prepared, the second step began with adding 100 µL of the
sample (i.e., supernatant from a dosed plate as described above) to each well in the
prepared plate from the previously described step. The prepared plate with sample was
covered with an adhesive strip and incubated at room temperature for two hours. After
the two-hour incubation period, the plate was then aspirated and washed three times with
the Wash Buffer used above. 100 µL of detection antibody (18 µg/mL of biotinylated
goat anti-rat TNF-α when reconstituted with 1.0 mL of the described Reagent Diluent)
was added to each well. The plate was covered with a new adhesive strip and incubated
at room temperature for two additional hours. The aspiration and wash procedure as
described above was used after the two-hour incubation period. 100 µL of StreptavidinHRP (1.0 mL of streptavidin conjugated to horseradish-peroxidase) was then added to
each well. The plate was covered and incubated at room temperature for 20 minutes.
After the 20 minute period, the same aspiration and wash technique was used. 100 µL of
substrate solution (1:1 mixture of Color Reagent A (H2O2) and Color Reagent B
(Tetramethylbenzidine)) (KPL SureBlue Reserve TMB 1-Component Microwell
Peroxidase Substrate) was then added to each well. The plate was incubated for 20
minutes at room temperature. 50 µL of stop solution (KPL TMB Stop Solution) was then
added to each well and gently tapped to ensure mixing. Afterwards, the plate was
immediately read on the Molecular Devices Spectra Max 190 plate reader set to 450 nm
with a wavelength correction set to 540 nm.
Two independent experiments were conducted with two separate samples (for
each dosed concentration) for each experiment. A standard curve was also developed
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(recombinant rat TNF-α reconstituted with reagent diluent) to compare measured values
against. The TNF-α production results were computed by comparing the absorbance
values of each dosed sample to that of the developed standard curve. The two separate
sample values were averaged as the mean of each independent experiment. The means of
the two independent experiments values were subsequently taken as the overall TNF-α
production.
IL-6 Assay.
The IL-6 Assay (R&D Systems, Inc. Catalog Number:DY506) was broken up into
two separate steps. The first step was the ELISA plate preparation with the capture
antibody. The second step consisted of adding a supernatant sample from a dosed plate
to the prepared plate for determination of IL-6 production. The dosed plate was done as
described in previous sections; however, a IL-6 stimulant was also used. The cellular
activator used was E. coli lipopolysaccharide (LPS) (Sigma-Aldrich). House explains
that for macrophages, the best cellular activator to use is LPS (1999:22). To determine
what concentration was needed to stimulate IL-6, a plate of LPS-dosed cells was done
(i.e., no particles) before the actual experiment involving copper nanoparticles began.
To prepare the plate (Greiner Microlon LE High Binding Plates) during the first
step, 100 µL of capture antibody (720 µg/mL of mouse anti-rat IL-6 reconstituted with
1.0 mL of PBS) was used to coat each well in a 96-well plate. After a 24-hour incubation
period at room temperature, the capture antibody was aspirated and each well was
washed with approximately 300 µL of wash buffer (Biosource 25x Wash Buffer) three
times. The plates were then blocked by the addition of 300 µL of reagent diluent (one
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percent BSA (Calbiochem) in PBS) to each well. The plate was incubated at room
temperature for one hour. After the one hour, the reagent diluent was aspirated and each
well was washed as described above with the wash buffer. This concluded the first step
of plate preparation.
After the plate was prepared, the second step began with adding 100 µL of the
sample (i.e., supernatant from a dosed plate as described above) to each well in the
prepared plate from the previously described step. The prepared plate with sample was
covered with an adhesive strip and incubated at room temperature for two hours. After
the two-hour incubation period, the plate was then aspirated and washed three times with
the Wash Buffer used above. 100 µL of detection antibody (72 µg/mL of biotinylated
goat anti-rat IL-6 when reconstituted with 1.0 mL of the described Reagent Diluent) was
added to each well. The plate was covered with a new adhesive strip and incubated at
room temperature for two additional hours. The aspiration and wash procedure as
described above was used after the two-hour incubation period. 100 µL of StreptavidinHRP (1.0 mL of streptavidin conjugated to horseradish-peroxidase) was then added to
each well. The plate was covered and incubated at room temperature for 20 minutes.
After the 20 minute period, the same aspiration and wash technique was used. 100 µL of
substrate solution (1:1 mixture of Color Reagent A (H2O2) and Color Reagent B
(Tetramethylbenzidine) (KPL SureBlue Reserve TMB 1-Component Microwell
Peroxidase Substrate) was then added to each well. The plate was incubated for 20
minutes at room temperature. 50 µL of stop solution (KPL TMB Stop Solution) was then
added to each well and gently tapped to ensure mixing. Afterwards, the plate was
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immediately read on the Molecular Devices Spectra Max 190 plate reader set to 450 nm
with a wavelength correction set to 540 nm.
Two independent experiments were conducted with two separate samples (for
each dosed concentration) for each experiment. A standard curve was also developed
(recombinant rat IL-6 reconstituted with reagent diluent) to compare measured values
against. The IL-6 production results were computed by comparing the absorbance values
of each dosed sample to that of the developed standard curve. The two separate sample
values were averaged as the mean of each independent experiment. The means of the
two independent experiments values were subsequently taken as the overall IL-6
production.
Dynamic Light Scattering
Copper nanoparticle stock solution samples (i.e., no exposure media) were placed
in Cuvettes (Sarstedt Co.) and a Zetasizer® Nano (Malvern Instruments) machine to
determine both average size and zeta potential. The purpose of DLS measurements is to
determine the average size of nanoparticles in solution. The size advertised by the
manufacturer (i.e., Cu-80 nanoparticles) may be the accurate size, but agglomeration of
particles in powder form, and also within the stock solution (sterile water) or exposure
media must be accounted for. Thus, DLS measurements must be made to determine
nanoparticle size used in the dosing procedures. Measurements were taken in sterile
water to give an accurate size measurement due to no presence of interferences such as
proteins found in exposure media. In addition, concentrations of copper nanoparticles in
exposure media were analyzed for size only in Zetasizer Nanoseries Folded Capillary
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Cells (Malvern Instruments). (Note: zeta potential could not be determined for samples
with exposure media due to conductivity incompatibilities within the Zetasizer® Nano).
Measurements in exposure media were done to simulate conditions as to what size
particle the cells were actually exposed to in exposure media. Finally, Mr. Michael
Moulton (AFRL/RHPB) accomplished all DLS measurement analysis during my
research.
Statistical Analysis
All statistical analysis was done in Microsoft Excel. After the completion of each
respective assay, the results from the microplate reader were downloaded into Excel. The
use of the Rejection Quotient, Q, was also used to determine outliers of data points after
the completion of each independent experiment using a 95 percent confidence level
(Rorabacher, 1991). Statistical significance was determined by using the students t test
(two-sample assuming unequal variances, two-tailed analysis), also at a 95 percent
confidence level.

47

IV. Results and Analysis
MTS Assay
Results of the MTS assay are expressed as the mean of at least two separate
samples (± Standard Deviation) derived from three independent experiments. Statistical
significance is indicated by an asterisk (*), based on p < 0.05 (using student’s t test)
compared to control (untreated) cells. The MTS assay showed that extremely low
concentrations of all copper nanoparticles (Cu-40, 60, and 80) produced toxic conditions
for rat alveolar macrophages. As seen in Figure 8 below, most cells were not viable after
exposure to only 2.5 µg/mL of all sizes of copper nanoparticles tested. In fact, toxicity
all sizes of copper nanoparticles was statistically significant as compared to the control
(untreated) cells at 7.5 and 10 µg/mL. Only Cu-40 nanoparticles showed no statistically
significant toxicity at 5 µg/mL. In addition, at 7.5 and 10 µg/mL, approximately only 20
percent of the alveolar macrophages were viable after exposure to all sized copper
nanoparticles. As mentioned, micron sized cadmium oxide (CdO) was used as a positive
control (results not shown) for each MTS experiment, because of its known toxic
properties as determined in previous studies.
In general, Cu-80 nanoparticles were slightly more toxic than Cu-40 and Cu-60
nanoparticles, specifically at higher nanoparticle doses (i.e., ≥ 5 µg/mL). However,
Figure 8 also shows that the toxicity of the copper nanoparticles was not size-dependent
(no significant difference in toxicity between each sized copper nanoparticles), but was
dose-dependent.
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Figure 8. Combined MTS results (Cu-40, 60 and 80 nanoparticles)
Furthermore, since grave toxicity was seen after exposure to copper nanoparticles,
it was assumed that alveolar macrophages would not survive and re-grow after a 24-hour
time point; thus, longer time points (i.e., 48 or 72 hours) were not examined. However,
since significant toxicity was seen at low copper nanoparticle concentrations at 24 hours,
the next step was to determine if toxicity would be evident at earlier time points. Thus, a
time study was conducted at time points to include one, two, three, four, six, and eight
hours, as described below.
Time Study
Results of the time study are expressed as the mean of at least four separate
samples (± Standard Deviation) derived from one experiment. Statistical significance
tests were not accomplished due to only one independent experiment being conducted.
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The time study used Cu-80 nanoparticles, primarily because of the time required to
conduct this experiment (i.e., all copper nanoparticle sizes would not be feasible), and
also because of the toxic properties described above (and below in the LDH analysis and
discussion). Cu-80 nanoparticles were somewhat more toxic than Cu-40 and Cu-60
nanoparticles. Figure 9 below shows toxicity to Cu-80 nanoparticles as early as three and
four hours, but only at significantly higher concentrations. Toxicity was also evident at a
time point of six hours even at lower nanoparticle concentrations. However, some
possible stimulation of cells at lower doses of Cu-80 nanoparticles was also observed
(i.e., MTS reduction above 100 percent).
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Figure 9. Cu-80 nanoparticle time study (≤ 8 hours)
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LDH Assay
Results of the LDH assay are expressed as the mean of at least three separate
samples (± Standard Deviation) derived from three independent experiments. Statistical
significance is indicated by an asterisk (*), based on p < 0.05 (using student’s t test)
compared to the control (untreated) cells. The LDH assay showed a tremendous increase
in membrane leakage in a dose-dependent manner. In addition, the LDH experiments, as
did the MTS assay, showed that a significant size-dependent toxic effect between the
different copper nanoparticles did not exist. However, of the three copper nanoparticles,
Cu-80 showed the most membrane leakage, as compared to Cu-40 and Cu-60
nanoparticles. As seen in Figure 10 below, toxicity of all copper nanoparticles was
statistically significant at 5, 7.5, and 10 µg/mL as compared to the control (untreated)
cells. Consequently, the large degree of membrane leakage in dose-dependent
concentrations from 1 to 10 µg/mL indicated that cellular necrosis occurred; cellular
apoptosis would have a weaker response in membrane leakage.
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Figure 10. Combined LDH results (Cu-40, 60 and 80 nanoparticles)
An additional goal of the MTS and LDH experiments was to determine what
concentrations to use for further experiments to include the two cytokine ELISA kits
(TNF-α and IL-6). The MTS and LDH experiments showed that severe toxicity was
evident at 5 µg/mL (see Figures 8 and 10, above). Thus, further experiments focused on
copper nanoparticle doses ≤ 5 µg/mL (i.e., 1, 2.5, and 5 µg/mL), primarily because a
measurement of a specific cytokine production would be limited to viable macrophages.
Reactive Oxygen Species
Results of the ROS experiments are expressed as the mean of at least three
separate samples (± Standard Deviation) derived from three independent experiments.
Statistical significance is indicated by an asterisk (*), based on p < 0.05 (using student’s t
test) compared to control (untreated) cells.
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Overall, only a slight increase in ROS production was observed, indicating
oxidative stress was not a significant mechanism of toxicity. General observations
include ROS production at the 6-hour time point greater than the 24-hour time point,
especially for Cu-80 nanoparticles (see Figure 13, below). However, as indicated in the
LDH analysis, large degrees of membrane leakage led to cellular necrosis and an
associated cellular leakage of the fluorescent product. This phenomenon could cause
greater time points (24 hours and large degrees of associated membrane leakage) to have
less ROS production than some lesser time points (6 hours). Also, the intensity of the
DFCH-DA probe could have decreased at the 24-hour time point and caused less ROS
production. In addition, with Cu-80 nanoparticles, the ROS production actually
decreased at the highest concentration of 10 µg/mL (see Figure 13, below); this
phenomenon can be attributed to the same cellular leakage indicating a decreased ROS
production (Hussain and Frazier, 2002:430). No measurement points were statistically
significant at the 24-hour time point, as compared to control (untreated) cells (see Figures
11, 12, and 14, below), except for the 1 and 10 µg/mL Cu-80 measurement points (see
Figure 13, below). However, statistically significant differences did exist at the 6-hour
time point to include both the 5 and 10 µg/mL exposure points for the Cu-40 exposure
(see Figure 11, below). In fact, most Cu-80 nanoparticles exposures (1, 2.5, 5, and 10
µg/mL) produced statistically significant differences at the 6-hour time point (see Figure
13, below). As seen in Figure 12 below, Cu-60 nanoparticles showed a large increase at
10 µg/mL; however, the standard deviation was extremely large, indicating a potential
measurement error.
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Figure 11. ROS production at 6 and 24 hours after exposure to Cu-40 nanoparticles
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Figure 12. ROS production at 6 and 24 hours after exposure to Cu-60 nanoparticles
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Figure 13. ROS production at 6 and 24 hours after exposure to Cu-80 nanoparticles
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Figure 14. ROS production at 6 and 24 hours after exposure to Positive Control
(hydrogen peroxide)
Although the positive control (hydrogen peroxide) for the 6-and-24 hour time
points showed a large increase in ROS production (see Figure 14, above), a greater
increase was expected in response to copper nanoparticles exposure due to previous ROS
experiments from the AFRL toxicological laboratory (unpublished data) using copper
nanoparticles (used PC12 cells as in vitro model). In addition, Ag (15-nm) nanoparticles
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induced ROS production fold of increases greater than six at 10 µg/mL (Hussain, et al.,
2005:980). After performing ROS experiments and further investigation, it was brought
to my attention that exposure media containing phenol-red may influence and weaken
actual increases in ROS production. Thus, ROS experiments were performed again using
exposure media not containing phenol-red as my original ROS experiments used
exposure media with phenol-red. Surprisingly, lower increases in ROS production were
observed when using the phenol-red free exposure media (results not shown).
Cytokine Analysis
The first step in optimizing each cytokine assay (TNF-α and IL-6) was
development of a standard curve (using recombinant rat TNF-α or IL-6 reconstituted with
Reagent Diluent, as described above in the Methodology section). The standard curve
using the four-parameter method produced R2 values of ≥ 0.98, indicating a highly
precise curve. The next step was to determine if copper nanoparticles induced TNF-α or
IL-6 production. If the copper nanoparticles did not induce cytokine production, the next
step was to determine a LPS concentration to stimulate alveolar macrophage production
of TNF-α or IL-6. The goal was to find an LPS concentration that would produce each
cytokine in suboptimal amounts. The LPS would be used as an agent to stimulate cells
while being exposed to copper nanoparticles. Exposing cells to LPS in the presence of
another chemical has been previously done. One experiment stimulated murine
macrophages with LPS while concurrently exposing the cells to mycophenolic acid to
measure TNF-α production (Jonsson and Carlsten, 2002:94). Other studies have used the
same approach (Major, et al., 2002:2457). The difference in cytokine production
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between the LPS stimulated cells alone and LPS + copper nanoparticle exposed cells
would be calculated to be the amount of cytokine production due to copper nanoparticle
exposure.
Summary of Cytokine Steps:
•

Standardize plates with TNF-α and IL-6 standards (Note: a standard curve was
developed for every experiment to account for potential errors between
various plate preparations)

•

Determine if copper nanoparticles induced cytokine production in alveolar
macrophages

•

If copper nanoparticles did not induce cytokine production, determine LPS
concentrations to produce suboptimal amounts of each cytokine

•

Determine cytokine production due to copper nanoparticles by stimulating
alveolar macrophages with LPS followed by exposure to copper nanoparticles

LPS also was used a positive control to indicate cytokine production as compared to
copper nanoparticle exposed cells only (i.e., not using LPS).
TNF-α Analysis.
Results of the TNF-α assay are expressed as the mean of two separate samples (±
Standard Deviation) derived from two independent experiments. Statistical significance
is indicated by an asterisk (*), based on p < 0.05 (using student’s t test) compared to LPS
treated cells. For the exposure to copper nanoparticles only (see Figure 15, below), there
was no statistically significant differences in TNF-α production as compared to control
(untreated) cells at concentrations of 1, 2.5, or 5 µg/mL. As mentioned above, LPS was
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used as a positive control to indicate TNF-α production (see Figure 16, below), while
exposure to copper nanoparticles did not produce TNF-α release. Thus, the next step was
to determine varying concentrations of LPS to stimulate alveolar macrophages to produce
TNF-α before subsequent exposure to copper nanoparticles.
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Figure 15. TNF-α produced after exposure to Cu-80 nanoparticles
For the TNF-α cytokine experiment, 0.1 ng/mL was determined to be the
suboptimal concentration (over a 24-hour time period) of LPS (an initial experiment
showed that as low as 25 ng/mL released excess amounts of TNF-α). 0.1 ng/mL of LPS
over a 24-hour time period showed production of approximately 50 pg/mL (see Figure
16, below). Dumortier and colleagues showed levels > 6000 pg/mL of TNF-α production
by macrophages (isolated from the peritoneal cavity) in response to 8 ng/mL of LPS for a
24-hour time period (2006:1526). Other studies used as much as 10 µg/mL of LPS for an
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ideal response from both human and rat alveolar macrophages (McRithie, et al.,
2000:646 and Losa Garcia, et al., 1999:49). Another experiment using the same cell line
of this research (rat alveolar macrophages (NR8383)), and the same R&D Systems
ELISA kit, showed that a 24-hour LPS exposure (100 ng/mL) produced approximately
10,545 pg/mL of TNF-α. However, Y. Li and colleagues (2000) used more cells
(1,000,000 cells/mL) as compared to these experiments (250,000 cells/mL), indicating
that more cells could potentially produce higher levels of cytokines. Another study
showed 5,200 pg/mL of TNF-α was produced (using same rat alveolar macrophage
(NR8383) cell line) after exposure to one µg/mL of LPS for 20 hours (Diabaté, et al.,
2002:325). However, ELISA techniques were not utilized and the author also did not
indicate how many cells/mL were initially plated (Diabaté, et al., 2002:324).
The production of TNF-α increased in a dose-dependent manner (after stimulated
with LPS), with 5 µg/mL concentrations producing the highest amount of TNF-α. This
was evident as exposure to Cu-80 nanoparticles was statistically significant at a 2.5
µg/mL concentration. TNF-α production was also statistically significant at 2.5 and 5
µg/mL exposure to Cu-60 nanoparticles. Also, as seen in Figure 16 below, the greatest
production of TNF-α (approximately 500 pg/mL above the LPS only exposure) was seen
after exposure to Cu-80 nanoparticles, as some size dependency was seen in TNF-α
production.
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Figure 16. Combined (Cu-40, 60, 80 and LPS) results of TNF-α produced
IL-6 Analysis.
Results of the IL-6 are expressed as the mean of two separate samples (± Standard
Deviation) derived from two independent experiments. Statistical significance is
indicated by an asterisk (*), based on p < 0.05 (using student’s t test) compared to LPS
treated cells. As was the case with TNF-α production, Cu-80 nanoparticles did not
stimulate a statistically significant amount of IL-6 production (results not shown) at
concentrations of 1, 2.5 or 5 µg/mL. The amount produced after exposure to Cu-80
nanoparticles was essentially equivalent to the zero dose. As mentioned above, LPS was
used as a positive control to indicate cytokine production (see Figure 17, below), while
exposure to copper nanoparticles did not produce IL-6 release. Thus, the next step was to
determine a LPS concentration to stimulate alveolar macrophages to produce suboptimal
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amounts of IL-6. For the IL-6 cytokine experiment, 100 ng/mL was determined to be the
suboptimal concentration (over a 24-hour time period) of LPS to be used during
subsequent experiments to stimulate alveolar macrophages. 100 ng/mL of LPS over a
24-hour time period showed production of approximately 5,160 pg/mL (see Figure 17,
below). Dumortier and colleagues showed levels > 100,000 pg/mL of IL-6 production by
macrophages (isolated from the peritoneal cavity) in response to 8 ng/mL of LPS for a
24-hour time period (2006:1526). Another study using the same cell line as this research
(rat alveolar macrophages (NR8383)) and the same R&D Systems ELISA kit, showed
that a 24-hour LPS exposure (100 ng/mL) produced approximately 62,400 pg/mL of IL6. However, in the Y. Li and colleagues (2000) experiment, more cells (1,000,000
cells/mL) were used as compared to my experiments (250,000 cells/mL), indicating that
more cells could potentially produce higher levels of cyokines.
Figure 17, below, shows that most copper nanoparticle concentrations induced the
production of IL-6 after initial LPS stimulation; however, only Cu-60 and Cu-80
nanoparticles (at 2.5 µg/mL) produced a statistically significant difference between the
LPS stimulated cells (100 ng/mL). Exposure to Cu-60 nanoparticles (at 2.5 µg/mL)
induced the highest amount of IL-6 production at approximately 2 ng/mL above the LPS
alone exposure. All copper nanoparticles showed an increase in IL-6 production from 1
to 2.5 µg/mL concentrations, but a decrease in IL-6 production from the 2.5 to 5 µg/mL
concentrations. Also, after conducting a preliminary IL-6 experiment, higher copper
nanoparticle concentrations produced lower levels of IL-6. For example, 10 µg/mL
produced lower amounts of IL-6 then at 5 µg/mL (results not shown). This indicated, and
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was supported by the above MTS viability study, that at 10 µg/mL, and to some degree at
5 µg/mL, most of the cells were not viable and unable to release IL-6. Thus, copper
nanoparticles concentrations less than 5 µg/mL induced higher levels of IL-6. This
phenomenon of separating cellular toxicity from cytokine production was also described
by Schmalz and others in a study of copper dental alloys in an in vitro study of human
fibroblast-keratinocytes (1998). The study showed that copper exposure resulted in only
25 percent cell viability; thus, the cells would not be alive to produce inflammatory
markers. Overall, the copper produced the pro-inflammatory markers, as measured by
the production of IL-6, only at the lower levels of copper exposure (Schmalz, et al.,
1998:1694).
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Figure 17. Combined (Cu-40, 60, 80 and LPS) results of IL-6 produced
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Dynamic Light Scattering
Dynamic Light Scattering (DLS) results for 0 and 24 (Table 2) hours are below.
Each table displays the average size, polydispersity index (PDI) and zeta potential of each
copper nanoparticle. As mentioned in the Methodology section above, 0-and 24-hour
time points were measured to determine differences in size over a 24-hour exposure
period to macrophages. The results show that the average size of each copper
nanoparticle is larger than the size given by the manufacturer. However, the size
measured was the average size; thus, some particles could be the stated size (i.e., 40 nm
for Cu-40 nanoparticles) while others agglomerated. In addition, as mentioned above,
other interferences (i.e., presence of proteins in exposure media) could be present that
influence the average reading size.
Table 2. DLS results, 0-and 24-hour time points
Average Size
Sample Type
(nm)
PDI
Zeta Potential (mV)
Time Point
0 hr / 24 hr
0 hr / 24 hr
0 hr / 24 hr
40nm in Sterile H2O
301 / 375
0.186 / 0.398
-13 / -2.78
40nm in Exposure Media
338 / 271
0.257 / 0.387
N/A / N/A
60nm in Sterile H2O
321 / 582
0.185 / 0.508
-9.56 / -10.1
60nm in Exposure Media
329 / 283
0.236 / 0.381
N/A / N/A
80nm in Sterile H2O
358 / 570
0.214 / 0.537
-7.07 / -12.9
80nm in Exposure Media
322 / 310
0.219 / 0.406
N/A / N/A
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V. Discussion
Nanomaterials have numerous useful properties; however, further research on
environmental and human health effects is needed. In fact, Material Safety Data Sheets
(MSDSs) for most nanomaterials simply list the properties and safety and health
precautions for the larger bulk material when the two can be entirely different (Colvin,
2003:1166). Overall, as nanoparticles show toxic effects to rodents, actual human
exposure must also be considered.
Research Questions and Conclusions
•

Are copper nanoparticles (40, 60, and 80 nm) toxic to alveolar macrophages?
o All copper nanoparticles showed significant toxicity for rat alveolar
macrophages. Concentrations as low as 2.5 µg/mL showed cell viability of
less than 50 percent. Also, the same concentration showed membrane leakage
increases of 50 percent. Concentrations of 10 µg/mL produced cell viability
of less than 20 percent and membrane leakage increases of approximately 75
percent. Thus, the large dose-dependent increases in membrane leakage
indicated cellular necrosis occurred, as opposed to apoptosis.

•

Is the toxicity size-dependent (i.e., difference in toxicity between the three sizes of
copper nanoparticles)?
o Overall, there was no significant size dependency in toxicity between the three
copper nanoparticles (40, 60, and 80 nm); however, the observed toxicity was
dose-dependent.
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•

Do copper nanoparticles induce reactive oxygen species (ROS)?
o Overall increases in ROS were low (only 2.5 fold increases) compared to
other studies involving nanoparticles, indicating low levels of oxidative stress.

•

Do copper nanoparticles induce an inflammatory response (using cytokines TNF-α
and IL-6 as indicators)?
o The results from the cytokine ELISA analysis show that copper nanoparticles
do not produce an inflammation response. However, when stimulated initially
(i.e., using LPS), exposure to copper nanoparticles did produce increased
levels of both TNF-α and IL-6.

Suggestions for Further Research
As mentioned, one in vivo experiment has been conducted with copper
nanoparticles (Chen, Z., et al., 2006). However, this experiment focused on ingestion
exposure; thus, further in vivo studies focusing on inhalation exposures are needed. Also,
a time study of all sizes of copper nanoparticles is needed (i.e., Cu-40 and Cu-60), as this
research focused on Cu-80 nanoparticles. A potential experiment involving the cytokine
ELISA (TNF-α and IL-6) kits would be to determine what response alveolar
macrophages, or other immune cell types, would have to a physiological stimulus (i.e.,
LPS) after exposure to copper nanoparticles and a set incubation period. Similar research
was conducted by Dumortier and colleagues using functionalized carbon nanotubes
(2006). In addition, to more effectively identify a LPS concentration to stimulate
alveolar macrophages to produce suboptimal concentrations of a specific cytokine, a time
study at time points less than 24 hours could be conducted. Also, another potential
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concern is the toxicity associated with LPS exposure to induce cytokine production
(Diabaté, et al., 2002). Thus, a side-by-side study could also examine the toxicity
associated with exposure to LPS while performing the specific ELISA analysis. Also,
transmission electron microscopy (TEM) studies have been accomplished on all sizes of
copper nanoparticles; however, no scanning electron microscopy (SEM) images, showing
the potential uptake of copper nanoparticles by rat alveolar macrophages, have been
accomplished. Finally, further research of the characterization of copper nanoparticles
will be of benefit in further biochemical studies.
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Appendix A. MTS Assay Protocol
1. Aspirate exposure media containing nanoparticle solutions (cells still adherent to
the well bottom)
2. Rinse each well three times with 200 µL of one percent Phosphate Buffered
Saline (PBS)
3. Add 100 µL of exposure media to each well
4. Add 20 µL of tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS(a)] to
each well
5. Lightly tap the plate to ensure adequate mixing of the reagent within the cells
6. Incubate plate for one to four hours at 37 degrees Celsius and five percent carbon
dioxide
7. Read the plate on the Molecular Devices Spectra Max 190 plate reader at a
wavelength of 490 nm
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Appendix B. LDH Assay Protocol
1. Add 50 µL of the supernatant from the 200 µL nanoparticle solution used for
dosing and place in a new 96-well plate
2. Add 50 µL of a positive control to empty wells
3. Add 50 µL of reagent (CytoTox-ONETM) to each well (supernatant and positive
control wells)
4. Lightly shake the new plate for approximately 30 seconds
5. Incubate plate in the dark for 10 minutes at room temperature
6. Add 25 µL of stop solution to each well
7. Lightly shake the plate for about 10 seconds
8. Immediately after adding stop solution, measure the fluorescent signal in the
Molecular Devices Spectra Max Gemini XS microplate reader, with an excitation
wavelength of 560 nm and read at a wavelength of 590 nm
Note: Keep plate out of the direct light
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Appendix C. Reactive Oxygen Species Protocol
1. Use black bottom 96-well plate for the initial cell dosing instead of a clear plate
2. After the 24-hour cell plating period, remove growth media and add 200 µL of
100 µM dichlorofluorescin diacetate (DCFH-DA) probe to each well
3. Incubate plate at 37 degrees Celsius and five percent carbon dioxide for 30
minutes
4. Remove DFCH-DA probe from each well
5. Add 200 µL of each respective nanoparticle solution to each well
6. Use a positive control of different molar strength (i.e., 100 to 2000 µM) hydrogen
peroxide
7. Cover plates with aluminum foil and place in incubator for different time
exposures (i.e., 6 and 24 hours)
8. Measure fluorescent signal on the Molecular Devices Spectra Max Gemini XS
microplate reader, with an excitation wavelength of 485 nm and read at a
wavelength of 530 nm
Note: Treat in a dark room with only a fluorescent red light

69

Appendix D. TNF-α ELISA Protocol
(Catalog Number: DY510 (R&D Systems, Inc.)
Materials and solutions required:
-

ELISA plates - Greiner Microlon LE High Binding Plates

-

Phosphate Buffered Saline

-

Wash Buffer - Biosource 25X Wash Buffer (WB01/Q110408)) – diluted with
deionized water to 1X

-

Reagent Diluent - 1% BSA Calbiochem (Cat#12659) in PBS

-

Substrate Solution - KPL SureBlue Reserve TMB 1-Component Microwell
Peroxidase Substrate (Cat #:53-00-03)

-

Stop Solution – KPL TMB Stop Solution (Cat#:50-85-05)

-

Stimulant - Lipopolysaccharide (LPS): Sigma-Aldrich (Cat#:L2630)

-

Capture Antibody - 720 µg/mL of mouse anti-rat TNF-α when reconstituted
with 1.0 mL of PBS. Dilute to a working concentration of 4.0 µg/mL in PBS,
without carrier protein.

-

Detection Antibody - 18 µg/mL of biotinylated goat anti-rat TNF-α when
reconstituted with 1.0 mL of reagent diluent. Dilute to a working concentration of
100 ng/mL in reagent diluent.

-

Standard - 150 ng/mL of recombinant rat TNF-α when reconstituted with 0.5 mL
of reagent diluent. Allow the standard to sit for a minimum of 15 minutes with
gentle agitation prior to making dilutions. A seven point standard curve using 2fold serial dilutions in reagent diluent, and a high standard of 4000 pg/mL is
recommended.
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-

Streptavidin-HRP - 1.0 mL of streptavidin conjugated to horseradish-peroxidase.
Dilute to the working concentration specified on the vial label using reagent
diluent.

Plate Preparation
1. Dilute the capture antibody to the working concentration in PBS without carrier
protein. Immediately coat a 96-well microplate with 100 µL per well of the diluted
capture antibody. Seal the plate and incubate overnight at room temperature.
2. Aspirate each well and wash with wash buffer, repeating the process two times for a
total of three washes. Wash by filling each well with wash buffer (400 µL) using a squirt
bottle, manifold dispenser or autowasher. Complete removal of liquid at each step is
essential for good performance. After the last wash, remove any remaining wash buffer
by aspirating or by inverting the plate and blotting it against clean paper towels.
3. Block plates by adding 300 µL of reagent diluent to each well. Incubate at room
temperature for a minimum of 1 hour.
4. Repeat the aspiration/wash as in step 2. The plates are now ready for sample addition.
Assay Procedure
1. Add 100 µL of sample or standards in reagent diluent, or an appropriate diluent, per
well. Cover with an adhesive strip and incubate 2 hours at room temperature.
2. Repeat the aspiration/wash as in step 2 of Plate Preparation.
3. Add 100 µL of the detection antibody, diluted in reagent diluent, to each well. Cover
with a new adhesive strip and incubate 2 hours at room temperature.
4. Repeat the aspiration/wash as in step 2 of Plate Preparation.
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5. Add 100 µL of the working dilution of Streptavidin-HRP to each well. Cover the plate
and incubate for 20 minutes at room temperature. Avoid placing the plate in direct light.
6. Repeat the aspiration/wash as in step 2.
7. Add 100 µL of substrate solution to each well. Incubate for 20 minutes at room
temperature. Avoid placing the plate in direct light.
8. Add 100 µL of stop solution to each well. Gently tap the plate to ensure thorough
mixing.
9. Determine the optical density of each well immediately, using a microplate reader set
to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength
correction is not available, subtract readings at 540 nm or 570 nm from the readings at
450 nm. This subtraction will correct for optical imperfections in the plate.
Readings made directly at 450 nm without correction may be higher and less accurate.
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Appendix E. IL-6 ELISA Protocol
(Catalog Number: DY506 (R&D Systems, Inc.)
Materials and solutions required:
-

ELISA High Binding plates - Greiner Microlon LE High Binding Plates

-

Phosphate Buffered Saline

-

Wash Buffer - Biosource 25X Wash Buffer (WB01/Q110408)) – diluted with
deionized water to 1X

-

Reagent Diluent - 1% BSA Calbiochem (Cat#12659) in PBS

-

Substrate Solution - KPL SureBlue Reserve TMB 1-Component Microwell
Peroxidase Substrate (Cat #:53-00-03)

-

Stop Solution – KPL TMB Stop Solution (Cat#:50-85-05)

-

Stimulant - Lipopolysaccharide (LPS): Sigma-Aldrich (Cat#:L2630)

-

Capture Antibody - 720 µg/mL of mouse anti-rat IL-6 when reconstituted with
1.0 mL of PBS. Dilute to a working concentration of 4.0 µg/mL in PBS, without
carrier protein.

-

Detection Antibody - 72 µg/mL of biotinylated goat anti-rat IL-6 when
reconstituted with 1.0 mL of reagent diluent. Dilute to a working concentration of
400 ng/mL in reagent diluent.

-

Standard - 250 ng/mL of recombinant rat IL-6 when reconstituted with 0.5 mL of
reagent diluent. Allow the standard to sit for a minimum of 15 minutes with
gentle agitation prior to making dilutions. A seven point standard curve using 2fold serial dilutions in reagent diluent, and a high standard of 8000 pg/mL is
recommended.
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-

Streptavidin-HRP - 1.0 mL of streptavidin conjugated to horseradish-peroxidase.
Dilute to the working concentration specified on the vial label using reagent
diluent.

Plate Preparation
1. Dilute the capture antibody to the working concentration in PBS without carrier
protein. Immediately coat a 96-well microplate with 100 µL per well of the diluted
capture antibody. Seal the plate and incubate overnight at room temperature.
2. Aspirate each well and wash with wash buffer, repeating the process two times for a
total of three washes. Wash by filling each well with wash buffer (400 µL) using a squirt
bottle, manifold dispenser or autowasher. Complete removal of liquid at each step is
essential for good performance. After the last wash, remove any remaining wash buffer
by aspirating or by inverting the plate and blotting it against clean paper towels.
3. Block plates by adding 300 µL of reagent diluent to each well. Incubate at room
temperature for a minimum of 1 hour.
4. Repeat the aspiration/wash as in step 2. The plates are now ready for sample addition.
Assay Procedure
1. Add 100 µL of sample or standards in reagent diluent, or an appropriate diluent, per
well. Cover with an adhesive strip and incubate 2 hours at room temperature.
2. Repeat the aspiration/wash as in step 2 of Plate Preparation.
3. Add 100 µL of the detection antibody, diluted in reagent diluent, to each well. Cover
with a new adhesive strip and incubate 2 hours at room temperature.
4. Repeat the aspiration/wash as in step 2 of Plate Preparation.
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5. Add 100 µL of the working dilution of Streptavidin-HRP to each well. Cover the plate
and incubate for 20 minutes at room temperature. Avoid placing the plate in direct light.
6. Repeat the aspiration/wash as in step 2.
7. Add 100 µL of substrate solution to each well. Incubate for 20 minutes at room
temperature. Avoid placing the plate in direct light.
8. Add 100 µL of stop solution to each well. Gently tap the plate to ensure thorough
mixing.
9. Determine the optical density of each well immediately, using a microplate reader set
to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength
correction is not available, subtract readings at 540 nm or 570 nm from the readings at
450 nm. This subtraction will correct for optical imperfections in the plate.
Readings made directly at 450 nm without correction may be higher and less accurate.
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